Search Page

1

Cite

Share

A review of nanotechnology-based approaches for breast cancer and triple-negative breast cancer.

Jain V, Kumar H, Anod HV, Chand P, Gupta NV, Dey S, Kesharwani SS. Jain V, et al. Among authors: kesharwani ss. J Control Release. 2020 Oct 10;326:628-647. doi: 10.1016/j.jconrel.2020.07.003. Epub 2020 Jul 10. J Control Release. 2020. PMID: 32653502 Review.

Cite

Share

2

Cite

Share

Overcoming multiple drug resistance in cancer using polymeric micelles.

Kesharwani SS, Kaur S, Tummala H, Sangamwar AT. Kesharwani SS, et al. Expert Opin Drug Deliv. 2018 Nov;15(11):1127-1142. doi: 10.1080/17425247.2018.1537261. Epub 2018 Oct 25. Expert Opin Drug Deliv. 2018. PMID: 30324813 Review.

Cite

Share

3

Cite

Share

Multifunctional approaches utilizing polymeric micelles to circumvent multidrug resistant tumors.

Kesharwani SS, Kaur S, Tummala H, Sangamwar AT. Kesharwani SS, et al. Colloids Surf B Biointerfaces. 2019 Jan 1;173:581-590. doi: 10.1016/j.colsurfb.2018.10.022. Epub 2018 Oct 10. Colloids Surf B Biointerfaces. 2019. PMID: 30352379 Review.

Cite

Share

4

Cite

Share

Formulation and Nanotechnology-Based Approaches for Solubility and Bioavailability Enhancement of Zerumbone.

Kesharwani SS, Bhat GJ. Kesharwani SS, et al. Medicina (Kaunas). 2020 Oct 23;56(11):557. doi: 10.3390/medicina56110557. Medicina (Kaunas). 2020. PMID: 33114101 Free PMC article. Review.

Cite

Share

5

Cite

Share

Design and evaluation of cabazitaxel loaded NLCs against breast cancer cell lines.

Chand P, Kumar H, Badduri N, Gupta NV, Bettada VG, Madhunapantula SV, Kesharwani SS, Dey S, Jain V. Chand P, et al. Among authors: kesharwani ss. Colloids Surf B Biointerfaces. 2021 Mar;199:111535. doi: 10.1016/j.colsurfb.2020.111535. Epub 2020 Dec 14. Colloids Surf B Biointerfaces. 2021. PMID: 33360926

Cite

Share

6

Cite

Share

Nobiletin as a Molecule for Formulation Development: An Overview of Advanced Formulation and Nanotechnology-Based Strategies of Nobiletin.

Kesharwani SS, Mallya P, Kumar VA, Jain V, Sharma S, Dey S. Kesharwani SS, et al. AAPS PharmSciTech. 2020 Aug 5;21(6):226. doi: 10.1208/s12249-020-01767-0. AAPS PharmSciTech. 2020. PMID: 32761293 Review.

Cite

Share

7

Cite

Share

Site-directed non-covalent polymer-drug complexes for inflammatory bowel disease (IBD): Formulation development, characterization and pharmacological evaluation.

Kesharwani SS, Ahmad R, Bakkari MA, Rajput MKS, Dachineni R, Valiveti CK, Kapur S, Jayarama Bhat G, Singh AB, Tummala H. Kesharwani SS, et al. J Control Release. 2018 Nov 28;290:165-179. doi: 10.1016/j.jconrel.2018.08.004. Epub 2018 Aug 21. J Control Release. 2018. PMID: 30142410

Cite

Share

8

Cite

Share

Dendritic Cell-Targeted Nanovaccine Delivery System Prepared with an Immune-Active Polymer.

Rajput MKS, Kesharwani SS, Kumar S, Muley P, Narisetty S, Tummala H. Rajput MKS, et al. Among authors: kesharwani ss. ACS Appl Mater Interfaces. 2018 Aug 22;10(33):27589-27602. doi: 10.1021/acsami.8b02019. Epub 2018 Aug 9. ACS Appl Mater Interfaces. 2018. PMID: 30048112

Cite

Share

9

Cite

Share

The Flavonoid Metabolite 2,4,6-Trihydroxybenzoic Acid Is a CDK Inhibitor and an Anti-Proliferative Agent: A Potential Role in Cancer Prevention.

Sankaranarayanan R, Valiveti CK, Kumar DR, Van Slambrouck S, Kesharwani SS, Seefeldt T, Scaria J, Tummala H, Bhat GJ. Sankaranarayanan R, et al. Among authors: kesharwani ss. Cancers (Basel). 2019 Mar 26;11(3):427. doi: 10.3390/cancers11030427. Cancers (Basel). 2019. PMID: 30917530 Free PMC article.

Cite

Share

10

Cite

Share

Salicylic acid metabolites and derivatives inhibit CDK activity: Novel insights into aspirin's chemopreventive effects against colorectal cancer.

Dachineni R, Kumar DR, Callegari E, Kesharwani SS, Sankaranarayanan R, Seefeldt T, Tummala H, Bhat GJ. Dachineni R, et al. Among authors: kesharwani ss. Int J Oncol. 2017 Dec;51(6):1661-1673. doi: 10.3892/ijo.2017.4167. Epub 2017 Oct 19. Int J Oncol. 2017. PMID: 29075787 Free PMC article.

Cite

Share